BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Katsanos K, Kitrou P, Spiliopoulos S, Maroulis I, Petsas T, Karnabatidis D. Comparative effectiveness of different transarterial embolization therapies alone or in combination with local ablative or adjuvant systemic treatments for unresectable hepatocellular carcinoma: A network meta-analysis of randomized controlled trials. PLoS One. 2017;12:e0184597. [PMID: 28934265 DOI: 10.1371/journal.pone.0184597] [Cited by in Crossref: 66] [Cited by in F6Publishing: 69] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Halfdanarson TR, Sonbol MB, Starr JS. Hepatobiliary carcinomas. Cardio-Oncology Practice Manual : a Companion to Braunwald 's Heart Disease 2023. [DOI: 10.1016/b978-0-323-68135-3.00051-9] [Reference Citation Analysis]
2 Garcia-Monaco RD, Chung JW, Vilgrain V, Bouattour M, Covey AM. Summary of key guidelines for locoregional treatment of HCC in Asia, Europe, South and North America. Br J Radiol 2022;95:20220179. [PMID: 35848758 DOI: 10.1259/bjr.20220179] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Breuer JA, Ahmed KH, Al-Khouja F, Macherla AR, Muthoka JM, Abi-Jaoudeh N. Interventional oncology: new techniques and new devices. Br J Radiol 2022;95:20211360. [PMID: 35731848 DOI: 10.1259/bjr.20211360] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Brown AM, Kassab I, Massani M, Townsend W, Singal AG, Soydal C, Moreno-Luna L, Roberts LR, Chen VL, Parikh ND. TACE versus TARE for patients with hepatocellular carcinoma: Overall and individual patient level meta analysis. Cancer Med 2022. [PMID: 35943116 DOI: 10.1002/cam4.5125] [Reference Citation Analysis]
5 Garg T, Shrigiriwar A, Habibollahi P, Cristescu M, Liddell RP, Chapiro J, Inglis P, Camacho JC, Nezami N. Intraarterial Therapies for the Management of Hepatocellular Carcinoma. Cancers (Basel) 2022;14:3351. [PMID: 35884412 DOI: 10.3390/cancers14143351] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Cisneros-garza L, González-huezo M, Moctezuma-velázquez C, Ladrón de Guevara-cetina L, Vilatobá M, García-juárez I, Alvarado-reyes R, Álvarez-treviño G, Allende-pérez S, Bornstein-quevedo L, Calderillo-ruiz G, Carrillo-martínez M, Castillo-barradas M, Cerda-reyes E, Félix-leyva J, Gabutti-thomas J, Guerrero-ixtlahuac J, Higuera-de la Tijera F, Huitzil-melendez D, Kimura-hayama E, López-hernández P, Malé-velázquez R, Méndez-sánchez N, Morales-ruiz M, Ruíz-garcía E, Sánchez-ávila J, Torrecillas-torres L. II Consenso mexicano de carcinoma hepatocelular. Parte II: tratamiento. Revista de Gastroenterología de México 2022;87:362-379. [DOI: 10.1016/j.rgmx.2022.01.006] [Reference Citation Analysis]
7 Cisneros-garza L, González-huezo M, Moctezuma-velázquez C, Ladrón de Guevara-cetina L, Vilatobá M, García-juárez I, Alvarado-reyes R, Álvarez-treviño G, Allende-pérez S, Bornstein-quevedo L, Calderillo-ruiz G, Carrillo-martínez M, Castillo-barradas M, Cerda-reyes E, Félix-leyva J, Gabutti-thomas J, Guerrero-ixtlahuac J, Higuera-de la Tijera F, Huitzil-melendez D, Kimura-hayama E, López-hernández P, Malé-velázquez R, Méndez-sánchez N, Morales-ruiz M, Ruíz-garcía E, Sánchez-ávila J, Torrecillas-torres L. The second Mexican consensus on hepatocellular carcinoma. Part II: Treatment. Revista de Gastroenterología de México (English Edition) 2022;87:362-379. [DOI: 10.1016/j.rgmxen.2022.01.004] [Reference Citation Analysis]
8 Danişan G, Arik E. Hepatosellüler Karsinomda İlaç Yüklenebilir Mikroküreler ile Yapılan Transarteriyel Kemoembolizasyonun Etkinliği: Tek Merkez Deneyimi. Düzce Tıp Fakültesi Dergisi 2022. [DOI: 10.18678/dtfd.1075822] [Reference Citation Analysis]
9 Sabrina V, Michael B, Jörg A, Peter B, Wolf B, Susanne B, Thomas B, Frank D, Matthias E, Markus F, Christian F, Paul F, Andreas G, Eleni G, Martin G, Elke H, Thomas H, Ralf-Thorsten H, Wolf-Peter H, Peter H, Achim K, Gabi K, Jürgen K, David K, Frank L, Hauke L, Thomas L, Philipp L, Andreas M, Alexander M, Oliver M, Silvio N, Huu Phuc N, Johann O, Karl-Jürgen O, Philipp P, Kerstin P, Philippe P, Thorsten P, Mathias P, Ruben P, Jürgen P, Jutta R, Peter R, Johanna R, Ulrike R, Elke R, Barbara S, Peter S, Irene S, Andreas S, Dietrich VS, Daniel S, Marianne S, Alexander S, Andreas S, Nadine S, Christian S, Andrea T, Anne T, Jörg T, Ingo VT, Reina T, Arndt V, Thomas V, Hilke V, Frank W, Oliver W, Heiner W, Henning W, Dane W, Christian W, Marcus-Alexander W, Peter G, Nisar M. S3-Leitlinie: Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 2022;60:e56-e130. [PMID: 35042248 DOI: 10.1055/a-1589-7568] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Liu B, Zhang Y, Chen H, Li W, Tsochatzis E. The combination of transcatheter arterial chemoembolisation (TACE) and thermal ablation versus TACE alone for hepatocellular carcinoma. Cochrane Database Syst Rev 2022;1:CD013345. [PMID: 34981511 DOI: 10.1002/14651858.CD013345.pub2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
11 Isaac EI, Hall J, Dault JB, Elbich J, Mcghee A, Fields EC. Transarterial Chemoembolization with LC Bead LUMI followed by Stereotactic Body Radiation Therapy in Treatment of Hepatocellular Carcinoma. Advances in Radiation Oncology 2022;7:100830. [DOI: 10.1016/j.adro.2021.100830] [Reference Citation Analysis]
12 Zheng S, Xie X, Guo X, Wu Y, Chen G, Chen X, Wang M, Xue T, Zhang B. Identification of a Pyroptosis-Related Gene Signature for Predicting Overall Survival and Response to Immunotherapy in Hepatocellular Carcinoma. Front Genet 2021;12:789296. [PMID: 34925465 DOI: 10.3389/fgene.2021.789296] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
13 Sun HC, Zhu XD. Downstaging Conversion Therapy in Patients With Initially Unresectable Advanced Hepatocellular Carcinoma: An Overview. Front Oncol 2021;11:772195. [PMID: 34869008 DOI: 10.3389/fonc.2021.772195] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
14 Zhang Q, Wang Y, Zhang J, Zhang W, Gong J, Ma R. TACE Combined with HIFU Versus Surgical Resection for Single Hepatocellular Carcinoma with Child-Pugh B Cirrhosis in Overall Survival and Progression-Free Survival: A Retrospective Study. Technol Cancer Res Treat 2021;20:15330338211060180. [PMID: 34855560 DOI: 10.1177/15330338211060180] [Reference Citation Analysis]
15 Brown ZJ, Hewitt DB, Pawlik TM. Combination therapies plus transarterial chemoembolization in hepatocellular carcinoma: a snapshot of clinical trial progress. Expert Opin Investig Drugs 2021;:1-13. [PMID: 34788184 DOI: 10.1080/13543784.2022.2008355] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Philips CA, Rajesh S, Nair DC, Ahamed R, Abduljaleel JK, Augustine P. Hepatocellular Carcinoma in 2021: An Exhaustive Update. Cureus 2021;13:e19274. [PMID: 34754704 DOI: 10.7759/cureus.19274] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
17 Reitano E, de'Angelis N, Bianchi G, Laera L, Spiliopoulos S, Calbi R, Memeo R, Inchingolo R. Current trends and perspectives in interventional radiology for gastrointestinal cancers. World J Radiol 2021; 13(10): 314-326 [PMID: 34786187 DOI: 10.4329/wjr.v13.i10.314] [Reference Citation Analysis]
18 Nyman SS, Creusen AD, Johnsson U, Rorsman F, Vessby J, Barbier CE. Peritumoral portal enhancement during transarterial chemoembolization: a potential prognostic factor for patients with hepatocellular carcinoma. Acta Radiol 2021;:2841851211041832. [PMID: 34665054 DOI: 10.1177/02841851211041832] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
19 Schoenberg MB, Li X, Li X, Han Y, Börner N, Koch D, Guba MO, Werner J, Bazhin AV. The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review. Int Immunopharmacol 2021;101:108220. [PMID: 34673334 DOI: 10.1016/j.intimp.2021.108220] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Apisarnthanarax S, Barry A, Cao M, Czito B, DeMatteo R, Drinane M, Hallemeier CL, Koay EJ, Lasley F, Meyer J, Owen D, Pursley J, Schaub SK, Smith G, Venepalli NK, Zibari G, Cardenes H. External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol 2021:S1879-8500(21)00233-2. [PMID: 34688956 DOI: 10.1016/j.prro.2021.09.004] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 9.0] [Reference Citation Analysis]
21 Morishita A, Tani J, Nomura T, Takuma K, Nakahara M, Oura K, Tadokoro T, Fujita K, Shi T, Yamana H, Matsui T, Takata T, Sanomura T, Nishiyama Y, Himoto T, Tomonari T, Moriya A, Senoo T, Takaguchi K, Masaki T. Efficacy of Combined Therapy with Drug-Eluting Beads-Transcatheter Arterial Chemoembolization Followed by Conventional Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma: A Multi-Center Study. Cancers (Basel) 2021;13:4605. [PMID: 34572832 DOI: 10.3390/cancers13184605] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
22 Samant H, Amiri HS, Zibari GB. Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. J Gastrointest Oncol 2021;12:S361-73. [PMID: 34422400 DOI: 10.21037/jgo.2020.02.08] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 6.5] [Reference Citation Analysis]
23 Liu H, Yang P, Jia Y. Optimal management of oligometastatic nasopharyngeal carcinoma. Eur Arch Otorhinolaryngol 2021. [PMID: 34089384 DOI: 10.1007/s00405-021-06918-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
24 Abi-Jaoudeh N, Dayyani F, Chen PJ, Fernando D, Fidelman N, Javan H, Liang PC, Hwang JI, Imagawa DK. Phase I Trial on Arterial Embolization with Hypoxia Activated Tirapazamine for Unresectable Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:421-34. [PMID: 34041204 DOI: 10.2147/JHC.S304275] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
25 Li X, Wang Y, Ye X, Liang P. Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development. Front Mol Biosci 2021;8:635243. [PMID: 33928118 DOI: 10.3389/fmolb.2021.635243] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 3.5] [Reference Citation Analysis]
26 Pang J, Hao G, Chen Y. Clinical effects and prognosis of stereotactic body radiotherapy combined with transarterial chemoembolization for massive hepatocellular carcinoma. Prec Radiat Oncol 2021;5:12-7. [DOI: 10.1002/pro6.1111] [Reference Citation Analysis]
27 Zheng S, Liu L, Xue T, Jing C, Xu X, Wu Y, Wang M, Xie X, Zhang B. Comprehensive Analysis of the Prognosis and Correlations With Immune Infiltration of S100 Protein Family Members in Hepatocellular Carcinoma. Front Genet 2021;12:648156. [PMID: 33815482 DOI: 10.3389/fgene.2021.648156] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
28 Agrawal R, Majeed M, Aqeel SB, Wang Y, Haque Z, Omar YA, Upadhyay SB, Gast T, Attar BM, Gandhi S. Identifying predictors and evaluating the role of steroids in the prevention of post-embolization syndrome after transarterial chemoembolization and bland embolization. Ann Gastroenterol. 2021;34:241-246. [PMID: 33654366 DOI: 10.20524/aog.2020.0566] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
29 Lemieux S, Buies A, F Turgeon A, Hallet J, Daigle G, Côté F, Provencher S. Effect of Yttrium-90 transarterial radioembolization in patients with non-surgical hepatocellular carcinoma: A systematic review and meta-analysis. PLoS One 2021;16:e0247958. [PMID: 33662011 DOI: 10.1371/journal.pone.0247958] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
30 Mao J, Tan Z, Pan X, Meng F. ASPP2 expression predicts the prognosis of patients with hepatocellular carcinoma after transcatheter arterial chemoembolization. Exp Ther Med 2021;21:397. [PMID: 33680119 DOI: 10.3892/etm.2021.9828] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
31 Roth GS, Benhamou M, Teyssier Y, Seigneurin A, Abousalihac M, Sengel C, Seror O, Ghelfi J, Ganne-Carrié N, Blaise L, Sutter O, Decaens T, Nault JC. Comparison of Trans-Arterial Chemoembolization and Bland Embolization for the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis. Cancers (Basel) 2021;13:812. [PMID: 33672012 DOI: 10.3390/cancers13040812] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
32 Bhangui P, Saigal S, Gautam D, Piplani T, Choudhary N, Chaudhary R, Yadav S, Thiagarajan S, Rastogi A, Saraf N, Nundy S, Soin AS. Incorporating Tumor Biology to Predict Hepatocellular Carcinoma Recurrence in Patients Undergoing Living Donor Liver Transplantation Using Expanded Selection Criteria. Liver Transpl 2021;27:209-21. [PMID: 33253492 DOI: 10.1002/lt.25956] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
33 Tagliaferri L, D’aviero A, Posa A, Iezzi R. Interventional Image-Guided HDR Brachytherapy as a Salvage Treatment: Exclusive or in Combination with Other Local Therapies. Manual on Image-Guided Brachytherapy of Inner Organs 2021. [DOI: 10.1007/978-3-030-78079-1_16] [Reference Citation Analysis]
34 Sanchez-Sanchez J, Martinez-Rodriguez A, Felipe JL, Hernandez-Martin A, Ubago-Guisado E, Bangsbo J, Gallardo L, Garcia-Unanue J. Effect of Natural Turf, Artificial Turf, and Sand Surfaces on Sprint Performance. A Systematic Review and Meta-Analysis. Int J Environ Res Public Health 2020;17:E9478. [PMID: 33348874 DOI: 10.3390/ijerph17249478] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
35 Logiurato B, Smirniotopoulos J, Darcy M, Charalel RA. Gastrointestinal Interventions: Then and Now. Digestive Disease Interventions 2020;04:401-408. [DOI: 10.1055/s-0040-1721455] [Reference Citation Analysis]
36 Li Y, Zhou F, Liu F, Wang M, Xing W. Experimental Study on Evaluation of Blood Supply Level and Embolization Ratio of Liver Cancer Based on I-Flow Software. Technol Cancer Res Treat 2020;19:1533033820970665. [PMID: 33174500 DOI: 10.1177/1533033820970665] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Pillai AA, Ramanathan M, Kulik L. Locoregional Therapies for Hepatocellular Carcinoma: What Has Changed in the Past Ten Years? Clin Liver Dis 2020;24:681-700. [PMID: 33012453 DOI: 10.1016/j.cld.2020.07.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
38 Zheng J, Cai J, Tao L, Kirih MA, Shen Z, Xu J, Liang X. Comparison on the efficacy and prognosis of different strategies for intrahepatic recurrent hepatocellular carcinoma: A systematic review and Bayesian network meta-analysis. International Journal of Surgery 2020;83:196-204. [DOI: 10.1016/j.ijsu.2020.09.031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
39 Aslam A, Do RKG, Kambadakone A, Spieler B, Miller FH, Gabr AM, Charalel RA, Kim CY, Madoff DC, Mendiratta-Lala M. Hepatocellular carcinoma Liver Imaging Reporting and Data Systems treatment response assessment: Lessons learned and future directions. World J Hepatol 2020; 12(10): 738-753 [PMID: 33200013 DOI: 10.4254/wjh.v12.i10.738] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
40 Zhang C, Yang M, Ericsson AC. The Potential Gut Microbiota-Mediated Treatment Options for Liver Cancer. Front Oncol 2020;10:524205. [PMID: 33163393 DOI: 10.3389/fonc.2020.524205] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
41 Bloj AF, Hălmaciu I, Suciu BA, Mărginean L. Treatment of Hepatocellular Carcinomas by Hepatic Transarterial Chemoembolization, Case Presentation and Review of the Literature. Acta Medica Transilvanica 2020;25:32-35. [DOI: 10.2478/amtsb-2020-0046] [Reference Citation Analysis]
42 Bhutiani N, O'Brien SJ, Priddy EE, Egger ME, Hong YK, Mercer MK, McMasters KM, Martin RCG, Potts MH, Scoggins CR. Correlating serum alpha-fetoprotein in hepatocellular carcinoma with response to Yttrium-90 transarterial radioembolization with glass microspheres (TheraSphere™). HPB (Oxford) 2020;22:1330-8. [PMID: 31917103 DOI: 10.1016/j.hpb.2019.12.007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
43 Abdallah MA, Wongjarupong N, Hassan MA, Taha W, Abdalla A, Bampoh S, Onyirioha K, Nelson M, Glubranson LA, Wiseman GA, Fleming CJ, Andrews JC, Mahipal A, Roberts LR. The efficacy, safety, and predictors of outcomes of transarterial radioembolization for hepatocellular carcinoma: a retrospective study. Expert Rev Gastroenterol Hepatol 2020;14:619-29. [PMID: 32490691 DOI: 10.1080/17474124.2020.1777856] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
44 Lanza E, Masetti C, Messana G, Muglia R, Pugliese N, Ceriani R, Lleo de Nalda A, Rimassa L, Torzilli G, Poretti D, D'Antuono F, Politi LS, Pedicini V, Aghemo A; Humanitas HCC Multidisciplinary Group. Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma. PLoS One 2020;15:e0232371. [PMID: 32555707 DOI: 10.1371/journal.pone.0232371] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 4.7] [Reference Citation Analysis]
45 Lanza E, Muglia R, Bolengo I, Poretti D, D'Antuono F, Ceriani R, Torzilli G, Pedicini V. Survival analysis of 230 patients with unresectable hepatocellular carcinoma treated with bland transarterial embolization. PLoS One 2020;15:e0227711. [PMID: 31935255 DOI: 10.1371/journal.pone.0227711] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
46 Schwertner A, Bergsland EK, Hope TA, Nakakura EK, Anwar M, Kohi MP, Fidelman N. Neuroendocrine Neoplasms. Image-Guided Interventions in Oncology 2020. [DOI: 10.1007/978-3-030-48767-6_10] [Reference Citation Analysis]
47 Sotirchos V, Soulen MC. Chemoembolization for Hepatocellular Carcinoma. Image-Guided Interventions 2020. [DOI: 10.1016/b978-0-323-61204-3.00034-8] [Reference Citation Analysis]
48 Kumar A, Acharya SK, Singh SP, Arora A, Dhiman RK, Aggarwal R, Anand AC, Bhangui P, Chawla YK, Datta Gupta S, Dixit VK, Duseja A, Kalra N, Kar P, Kulkarni SS, Kumar R, Kumar M, Madhavan R, Mohan Prasad VG, Mukund A, Nagral A, Panda D, Paul SB, Rao PN, Rela M, Sahu MK, Saraswat VA, Shah SR, Shalimar, Sharma P, Taneja S, Wadhawan M; INASL Task-Force on Hepatocellular Carcinoma. 2019 Update of Indian National Association for Study of the Liver Consensus on Prevention, Diagnosis, and Management of Hepatocellular Carcinoma in India: The Puri II Recommendations. J Clin Exp Hepatol 2020;10:43-80. [PMID: 32025166 DOI: 10.1016/j.jceh.2019.09.007] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
49 Afaq S, Soni JM, Pillai AK. New Loco Regional Approaches to Treat Liver Cancer. Liver Diseases 2020. [DOI: 10.1007/978-3-030-24432-3_63] [Reference Citation Analysis]
50 van Roekel C, Braat AJAT, Smits MLJ, Bruijnen RCG, de Keizer B, Lam MGEH. Radioembolization. Clinical Nuclear Medicine 2020. [DOI: 10.1007/978-3-030-39457-8_36] [Reference Citation Analysis]
51 Inchingolo R, Posa A, Mariappan M, Spiliopoulos S. Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions. World J Gastroenterol 2019;25:4614-28. [PMID: 31528090 DOI: 10.3748/wjg.v25.i32.4614] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 47] [Article Influence: 11.8] [Reference Citation Analysis]
52 Inchingolo R, Posa A, Mariappan M, Spiliopoulos S. Locoregional treatments for hepatocellular carcinoma: Current evidence and future directions. World J Gastroenterol 2019;25:4614-28. [PMID: 31528090 DOI: 10.3748/wjg.v25.i32.4614] [Reference Citation Analysis]
53 Ni J, Fang Z, An C, Sun H, Huang Z, Zhang T, Jiang X, Chen Y, Xu L, Huang J. Comparison of albumin-bilirubin grade, platelet-albumin-bilirubin grade and Child-Turcotte-Pugh class for prediction of survival in patients with large hepatocellular carcinoma after transarterial chemoembolization combined with microwave ablation. International Journal of Hyperthermia 2019;36:840-52. [DOI: 10.1080/02656736.2019.1646927] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
54 Mondaca S, Yarmohammadi H, Kemeny NE. Regional Chemotherapy for Biliary Tract Tumors and Hepatocellular Carcinoma. Surg Oncol Clin N Am 2019;28:717-29. [PMID: 31472915 DOI: 10.1016/j.soc.2019.06.008] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
55 Viveiros P, Riaz A, Lewandowski RJ, Mahalingam D. Current State of Liver-Directed Therapies and Combinatory Approaches with Systemic Therapy in Hepatocellular Carcinoma (HCC). Cancers (Basel) 2019;11:E1085. [PMID: 31370248 DOI: 10.3390/cancers11081085] [Cited by in Crossref: 31] [Cited by in F6Publishing: 36] [Article Influence: 7.8] [Reference Citation Analysis]
56 Mendoza E, Abi-jaoudeh N. Liver Directed Therapies. Medical Imaging and Image-Guided Interventions 2019. [DOI: 10.5772/intechopen.75163] [Reference Citation Analysis]
57 Saffo S, Taddei TH. Systemic Management for Advanced Hepatocellular Carcinoma: A Review of the Molecular Pathways of Carcinogenesis, Current and Emerging Therapies, and Novel Treatment Strategies. Dig Dis Sci 2019;64:1016-29. [PMID: 30887150 DOI: 10.1007/s10620-019-05582-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 5.0] [Reference Citation Analysis]
58 Wagner MG, Laeseke P, Speidel MA. Deep learning based guidewire segmentation in x-ray images. Medical Imaging 2019: Physics of Medical Imaging 2019. [DOI: 10.1117/12.2512820] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
59 Iezzi R, Pompili M, Posa A, Carchesio F, Siciliano M, Annicchiarico BE, Agnes S, Giuliante F, Garcovich M, Cerrito L, Ponziani FR, Basso M, Cassano A, Rapaccini GL, De Gaetano AM, Gasbarrini A, Manfredi R; HepatoCATT Study Group for the Multidisciplinary Management of HCC. Interventional oncology treatments for unresectable early stage HCC in patients with a high risk for intraprocedural bleeding: Is a single-step combined therapy safe and feasible? Eur J Radiol 2019;114:32-7. [PMID: 31005173 DOI: 10.1016/j.ejrad.2019.02.030] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
60 Cross T, Evans JC. Transarterial Embolization Therapies in Hepatocellular Carcinoma: Principles of Management. Liver Cancers 2019. [DOI: 10.1007/978-3-319-92216-4_10] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
61 Shen L, Xi M, Zhao L, Zhang X, Wang X, Huang Z, Chen Q, Zhang T, Shen J, Liu M, Huang J. Combination Therapy after TACE for Hepatocellular Carcinoma with Macroscopic Vascular Invasion: Stereotactic Body Radiotherapy versus Sorafenib. Cancers (Basel) 2018;10:E516. [PMID: 30558224 DOI: 10.3390/cancers10120516] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
62 Lin YL. Proton beam therapy in apneic oxygenation treatment of an unresectable hepatocellular carcinoma: A case report and review of literature. World J Hepatol 2018; 10(10): 772-779 [PMID: 30386470 DOI: 10.4254/wjh.v10.i10.772] [Reference Citation Analysis]
63 Tian G, Yang S, Yuan J, Threapleton D, Zhao Q, Chen F, Cao H, Jiang T, Li L. Comparative efficacy of treatment strategies for hepatocellular carcinoma: systematic review and network meta-analysis. BMJ Open. 2018;8:e021269. [PMID: 30341113 DOI: 10.1136/bmjopen-2017-021269] [Cited by in Crossref: 26] [Cited by in F6Publishing: 30] [Article Influence: 5.2] [Reference Citation Analysis]
64 Zeng JY, Piao XH, Zou ZY, Yang QF, Qin ZL, Chen JB, Zhou L, Niu LZ, Liu JG. Cryoablation with drug-loaded bead embolization in the treatment of unresectable hepatocellular carcinoma: safety and efficacy analysis. Oncotarget 2018;9:7557-66. [PMID: 29484132 DOI: 10.18632/oncotarget.24029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
65 Narsinh KH, Duncan DP, Newton IG, Minocha J, Rose SC. Liver-directed therapy for hepatocellular carcinoma. Abdom Radiol (NY) 2018;43:203-17. [PMID: 29230556 DOI: 10.1007/s00261-017-1435-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]